中国儿童水痘突破性感染率及两剂水痘疫苗效果
该研究在宁波对2008至2013年出生的107324名本地儿童进行回顾性调查,评估水痘突破性感染率及两剂疫苗效果。结果显示,两剂接种突破性感染率为0.04%,一剂为0.37%;两剂疫苗对所有水痘的保护效果为98.7%,一剂为50.3%,增量效果为97.4%。作者建议在中国儿童中推荐普遍接种两剂水痘疫苗。
要点
- 两剂水痘疫苗突破性感染率为0.04%,一剂为0.37%。
- 两剂疫苗对所有水痘的保护效果为98.7%(95%CI:98.1%-99.1%)。
- 一剂疫苗保护效果为50.3%(95%CI:39.8%-59.0%),两剂相比一剂的增量效果为97.4%(95%CI:96.2%-98.2%)。
核心结论
- 两剂水痘疫苗方案对所有水痘提供极好保护,作者建议在中国儿童中推荐普遍接种两剂水痘疫苗以预防水痘疾病。
研究设计与样本
- 回顾性调查,纳入宁波市主动监测区2008至2013年出生的本地儿童,共107324名。
- 2009至2016年通过宁波市免疫规划信息系统收集人口学和水痘疫苗接种信息,通过中国疾病预防控制信息系统获取水痘感染信息。
- 采用逻辑回归估计水痘疫苗效果(VE)。
主要发现
- 107324名本地儿童纳入队列分析,其中95.11%无水痘疾病史的儿童在2009至2016年至少接种1剂水痘疫苗。
- 所有接种儿童总突破性水痘感染率(BVR)为0.37%,两剂接种为0.04%。
- 一剂疫苗年度BVR范围为0.01%至0.49%,两剂为0.01%至0.02%。
- 2014年实施两剂接种后,未接种儿童(趋势P < 0.001)和一剂儿童(趋势P = 0.003)的感染率均下降。
- 一剂对所有水痘的VE为50.3%(95%CI:39.8%-59.0%,P < 0.001),两剂为98.7%(95%CI:98.1%-99.1%,P < 0.001),与一剂相比的增量VE为97.4%(95%CI:96.2%-98.2%,P < 0.001)。
关键数值与推荐
- 一剂水痘疫苗对所有水痘的保护效果为50.3%(95%CI:39.8%-59.0%,P < 0.001)。
- 两剂水痘疫苗对所有水痘的保护效果为98.7%(95%CI:98.1%-99.1%,P < 0.001)。
- 两剂相比一剂的增量保护效果为97.4%(95%CI:96.2%-98.2%,P < 0.001)。
临床怎么用
- 作者建议在中国儿童中推荐普遍接种两剂水痘疫苗以预防水痘疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 2-dose varicella vaccination has been available in Ningbo city, China since 2014 in the private sector. This study aimed to evaluate the breakthrough varicella infection rate, and to examine overall and incremental effectiveness of 2-dose varicella vaccination among Chinese children. METHODS: A retrospective investigation was done among native children born from 2008 to 2013 in active surveillance area in Ningbo, China. Between 2009 and 2016, demographic information and data on varicella vaccination were collected by Ningbo's Immunization Information System, and information of varicella infections were obtained from China Information System for Disease Control and Prevention. The logistic regression was conducted to estimate varicella vaccine effectiveness (VE). RESULT: A total of 107,324 local children were enrolled in the cohort analysis and 95.11% of these children with no varicella disease history received at least 1-dose varicella vaccine from 2009 to 2016. The total breakthrough varicella infection rate (BVR) was 0.37% for all the vaccinated children and 0.04% for 2-dose vaccination. The annual BVR ranged from 0.01% to 0.49% for 1-dose of varicella vaccine and from 0.01% to 0.02% for 2-dose. The infection rates both in the unvaccinated children and the 1-dose children were decreasing after 2-dose vaccination implemented in 2014 (Unvaccinated: P < 0.001 for trend; 1-dose: P = 0.003 for trend). The VE against all varicella was 50.3% (95% CI: 39.8%-59.0%) for 1-dose (P < 0.001) and 98.7% (95% CI: 98.1%-99.1%) for 2-dose (P < 0.001), and the incremental VE was 97.4% (95% CI: 96.2%-98.2%) compared with 1-dose (P < 0.001). CONCLUSION: The 2-dose regimen provided excellent protection to prevent all varicella, and the universal 2-dose regimen of varicella vaccine should be recommended to prevent the varicella disease among children in China.
引用
- Pan X, Shu M, Ma R, et al. Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China. Vaccine. 2018. PMID: 30104113. doi:10.1016/j.vaccine.2018.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。